Treatment of primary effusion lymphoma with highly active antiviral therapy in the setting of HIV infection

AIDS

Volumn 22, Issue 10, 2008, Pages 1236-1237

  Ripamonti, Diego ^a   Marini, Basilio ^a   Rambaldi, Alessandro ^b   Suter, Fredy ^a  

^a Antiviral Therapy Unit   (Italy)

^b Hematology Division   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; LAMIVUDINE;

ADULT; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; REMISSION; THORACOCENTESIS; THORAX RADIOGRAPHY; B CELL LYMPHOMA;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, PRIMARY EFFUSION; MALE;

EID: 50949110610     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282fc732b     Document Type: Letter

References (15)

1. Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcomaassociated herpes virus. Blood 1996; 88:645-656.
2. Chen YB, Rahemtullah A, Hochberg E. Primary effusion lymphoma. Oncologist 2007; 12:569-576; Review.
3. Simonelli C, Spina M, Cinelli R, Talamini R, Tedeschi R, Gloghini A, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol 2003; 21:3948-3954.
4. Brimo F, Michel RP, Khetani K, Auger M. Primary effusion lymphoma: a series of 4 cases and review of the literature with emphasis on cytomorphologic and immunocytochemical differential diagnosis. Cancer 2007; 111:224-233.
5. Valencia ME, Martinez P, Moreno V, Laguna F, LahozJG. AIDSrelated body cavity-based lymphomas, herpesvirus-8 and HIV infection: a study of seven cases. AIDS 1999; 13:2603-2605.
6. Oksenhendler E, Clauvel JP, Jouveshomme S, Davi F, Mansour G. Complete remission of a primary effusion lymphoma with antiretroviral therapy. Am J Hematol 1998; 57:266.
7. Boulanger E, Gerard L, Gabarre J, Molina JM, Rapp C, Abino JF, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 2005; 23:4372-4380.
8. Simonelli C, Tedeschi R, Gloghini A, Bortolin MT, Spina M, Bidol i E, et al. Characterization of immunologic and virological parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy. Clin Infect Dis 2005; 40:1022-1027.
9. Spina M, Gaidano G, Carbone A, Capello D, Tirelli U. Highly active antiretroviral therapy in human herpesvirus-8-related body-cavity-based lymphoma. AIDS 1998; 12:955-956.
10. Luppi M, Trovato R, Barozzi P, Vallisa D, Rossi G, Re A, Ravazzini L, et al. Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir. Leukemia 2005; 19:473-476.
11. Hocqueloux L, Agbalika F, Oksenhendler E, Molina JM. Longterm remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS 2001; 15:280-282.
12. Crum-Cianflone NF, Wallace MR, Looney D. Successful secondary prophylaxis for primary effusion lymphoma with human herpesvirus 8 therapy. AIDS 2006; 20:1567-1569.
13. Dupont C, Vasseur E, Beauchet A, Aegerter P, Berthe H, de Truchis P, et al. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodeficience humaine. AIDS 2000; 14:987-993.
14. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study. BMJ 1999; 319:23-24.
15. Polesel J, Clifford GM, Rickenbach M, Dal Maso L, Battegay M, Bouchardy C, et al. Swiss HIV Cohort Study. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS 2008; 22:301-306.